New CAR-T therapy targets hard-to-treat blood cancers in early trial
NCT ID NCT07365059
First seen Jan 29, 2026 · Last updated Apr 30, 2026 · Updated 12 times
Summary
This early-phase study tests a new treatment called GPRC5D CAR-T cell therapy for people with plasma cell disorders (like multiple myeloma) that have come back or stopped responding to other treatments. About 18 participants will receive the therapy to see if it is safe and shrinks the cancer. Researchers will also track how long the cells last in the body and any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL DYSCRASIAS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.